By Fineline Cube Amoy Diagnostics Co., Ltd. (SHE: 300685) announced in collaboration with Japanese partners Riken Genesis Co., Ltd. and Precision Medicine Asia Co., Ltd. that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved AmoyDx’ PCR11 as a companion diagnostic (CDx) for Johnson & Johnson’s Rybrevant (amivantamab) in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | MHLW (Japan) |
| Approval Type | Companion diagnostic (CDx) approval |
| Product | PCR11 gene companion diagnostic reagent |
| Indication | Detection of EGFR exon 20 insertion mutations in NSCLC |
| Therapeutic Pairing | Rybrevant (amivantamab) + chemotherapy |
| Collaborators | Riken Genesis Co., Ltd. and Precision Medicine Asia Co., Ltd. |
Product Profile & Technology
- Platform: Innovative PCR-based technology developed by AmoyDx
- Multiplex Capability: Simultaneously detects mutations in 11 key driver genes: EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2, and NTRK3
- Clinical Utility: Seven genes (EGFR, ALK, ROS1, BRAF, MET exon 14 skipping mutation, KRAS, and RET) already approved to guide therapy with over 20 targeted lung cancer drugs
- New Indication: Specifically identifies patients with unresectable, advanced, or recurrent NSCLC harboring EGFR exon 20 insertion mutations who may benefit from Rybrevant treatment
- Market Differentiation: Comprehensive lung cancer genomic profiling in a single test with regulatory backing for multiple therapeutic indications
Clinical & Commercial Significance
| Aspect | Details |
|---|---|
| Patient Population | NSCLC patients with EGFR exon 20 insertion mutations (historically difficult-to-treat subgroup) |
| Therapeutic Expansion | Extends Rybrevant’s approved use beyond EGFR exon 19 deletions and exon 21 L858R substitution mutations |
| Diagnostic Gap Addressed | Provides validated testing method for identifying eligible patients for this specific targeted therapy |
| Precision Medicine Impact | Enables more precise patient selection, potentially improving treatment outcomes and reducing unnecessary therapy |
The approval represents a significant milestone in AmoyDx’s international expansion strategy, marking its entry into the Japanese precision oncology diagnostics market through strategic partnerships with established local players.
Market Impact & Outlook
- Japan NSCLC Market: Estimated 85,000 new lung cancer cases annually, with ~4-10% harboring EGFR exon 20 insertion mutations
- Competitive Landscape: Positions AmoyDx against established global CDx providers in Japan’s sophisticated molecular diagnostics market
- Revenue Potential: Expected to generate ¥800 million–¥1.2 billion ($5.5–8.2 million) in annual revenue from this indication alone
- Strategic Value: Establishes AmoyDx as a global player in companion diagnostics with regulatory approvals spanning multiple jurisdictions
- Future Opportunities: Platform technology enables rapid expansion to additional biomarker-drug pairings as new targeted therapies gain approval
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for AmoyDx’s PCR11 companion diagnostic. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and changes in clinical practice guidelines.-Fineline Info & Tech